期刊文献+

替诺福韦酯抗病毒治疗对慢性乙型肝炎患者病毒特异性CD8^(+)T细胞功能的影响 被引量:4

Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8^(+)T Cells function in patients with chronic hepatitis B
原文传递
导出
摘要 目的观察替诺福韦酯(TDF)抗病毒治疗对HBeAg阳性慢性乙型肝炎患者外周血HBV特异性CD8^(+)T细胞功能的影响,评估其与HBeAg血清学阴转的相关性。方法纳入2016年10月至2018年7月就诊的HLA-A02限制性HBeAg阳性慢性乙型肝炎患者63例,予以TDF(300 mg/d)抗病毒治疗,分选基线和治疗48周时外周血CD8^(+)T细胞,流式细胞术检测外周血T细胞计数,酶联免疫斑点试验检测分泌穿孔素、颗粒酶B和γ干扰素(IFN-γ)的HBV特异性CD8^(+)T细胞频数,建立HBV特异性CD8^(+)T细胞与HepG2.2.15细胞直接接触和间接接触共培养系统,检测培养上清液中HBV DNA,通过检测乳酸脱氢酶水平计算靶细胞死亡率,酶联免疫吸附试验检测细胞因子表达,评估病毒特异性CD8^(+)T细胞的细胞杀伤和非细胞杀伤功能。2组计量资料比较采用t检验或配对t检验。结果TDF治疗48周时病毒学应答率为100%,生化学应答率为90.48%(57/63),HBeAg阴转率为25.40%(16/63)。外周血T细胞计数在TDF治疗48周时与基线及对照组比较差异均无统计学意义(P>0.05)。TDF治疗48周时,CHB患者分泌穿孔素、颗粒酶B和IFN-γ的HBV特异性CD8^(+)T细胞频数较基线显著升高(P<0.001),HBeAg阴转的CHB患者病毒特异性CD8^(+)T细胞分泌穿孔素、颗粒酶B和IFN-γ的频数亦显著高于HBeAg未阴转的患者(P<0.05)。在直接接触和间接接触培养系统中,TDF治疗48周时HBV特异性CD8^(+)T细胞均可诱导HepG2.2.15细胞培养上清液中HBV DNA显著下降(P<0.001),分泌IFN-γ和白细胞介素-2的水平显著升高(P<0.05),但仅在直接接触共培养系统中病毒特异性CD8^(+)T细胞诱导HepG2.2.15细胞死亡的比例升高(21.7%±6.18%比16.1%±4.15%,P<0.001)。HBeAg阴转的CHB患者HBV特异性CD8^(+)T细胞较HBeAg未阴转患者诱导HBV DNA下降水平更显著(P<0.001)、IFN-γ分泌水平升高(P<0.05),但靶细胞死亡比例在HBeAg阴转和未阴转患者之间的差异无统计学意义(P>0.05)。结论TDF治疗过程中,伴随病毒载量下降,病毒特异性CD8^(+)T细胞的细胞杀伤和非细胞杀伤功能均显著增强,且与HBeAg阴转密切相关。 Objective To observe the effect of tenofovir disoproxil fumarate(TDF)antiviral therapy on HBV-specific CD8^(+)T cell function in peripheral blood of patients with HBeAg-positive chronic hepatitis B,and to assess its correlation with HBeAg sero-negativeness.Methods Sixty-three cases with HLA-A02 restricted HBeAg-positive chronic hepatitis B who received TDF(300 mg/d)antiviral therapy were enrolled from October 2016 to July 2018.The peripheral blood CD8^(+)T cells were separated at baseline and 48 weeks after treatment.The peripheral blood T cells count were detected by flow cytometry.The frequency of HBV-specific CD8^(+)T cells secreting perforin,granzyme B,and interferon-γ(IFN-γ)were detected by enzyme-linked immunoblotting test.Direct and indirect contact co-culture system was established between HBV-specific CD8^(+)T cells and HepG2.2.15 cells.HBV DNA was detected in the culture supernatant.Target cell mortality was calculated by lactate dehydrogenase level.Cytokines expression was detected by enzyme-linked immunosorbent assay.Virus-specific CD8^(+)T cells cytokilling and non-cytokilling functions were evaluated.Measurement data of the two groups were compared by t-test or paired t-test.Results Viral response,biochemical response,and HBeAg seroconversion rate at 48 weeks of TDF treatment were 100%,90.48%(57/63),and 25.40%(16/63),respectively.There was no statistically significant difference in peripheral blood T cell count when compared with baseline and control group at 48 weeks of TDF treatment(P>0.05).At 48 weeks of TDF treatment,the frequency of HBV-specific CD8^(+)T cells secreting perforin,granzyme B,and IFN-γin CHB patients was significantly higher than baseline(P<0.001).Furthermore,the frequency of HBV-specific CD8^(+)T cells secreting perforin,granzyme B,and IFN-γwas also significantly higher in CHB patients with HBeAg negative than that of non-negative(P<0.05).HBV-specific CD8^(+)T cells had induced significant down-regulation of HBV DNA in the supernatant of HepG2.2.15 cell culture(P<0.001)and remarkable IFN-γand interleukin-2 secretion(P<0.05)at 48 weeks of TDF therapy in direct and indirect contact co-culture system.However,HepG2.2.15 cells death rate induced by virus-specific CD8^(+)T cells was increased only in the direct contact co-culture system(21.7%±6.18%vs.16.1%±4.15%,P<0.001).Compared with HBeAg non-negative patients,HBeAg negative CHB patients with HBV-specific CD8^(+)T cells had induced a strong decrease in HBV DNA(P<0.001)and an increase in IFN-γsecretion level(P<0.05).However,the target cell death proportion difference between HBeAg negative and non-negative patients was not statistically significant(P>0.05).Conclusion During TDF treatment,with the viral load reduction,virus-specific CD8^(+)T cells cytokilling and non-cytokilling functions are significantly enhanced,and are closely related to HBeAg negative.
作者 段树鹏 朱利红 侯丽娟 王宏伟 宋新文 郝洁 Duan Shupeng;Zhu Lihong;Hou Lijuan;Wang Hongwei;Zhu Xinwen;Hao Jie(Department of Infectious Diseases,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Department of Obstetrics and Gynecology,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Medical Section,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)
出处 《中华肝脏病杂志》 CSCD 北大核心 2021年第5期421-426,共6页 Chinese Journal of Hepatology
基金 河南省医学科技攻关计划项目(201303106)。
关键词 慢性乙型肝炎 抗病毒 免疫应答 Chronic hepatitis B Antiviral Immune response
  • 相关文献

参考文献3

二级参考文献26

  • 1Peng Hu,Jia Shang,Wenhong Zhang,Guozhong Gong,Yongguo Li,Xinyue Chen,Jianning Jiang,Qing Xie,Xiaoguang Dou,Yongtao Sun,Yufang Li,Yingxia Liu,Guozhen Liu,Dewen Mao,Xiaoling Chi,Hong Tang,Xiaoou Li,Yao Xie,Xiaoping Chen,Jiaji Jiang,Ping Zhao,Jinlin Hou,Zhiliang Gao,Huimin Fan,Jiguang Ding,Dazhi Zhang,Hong Ren.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog:New Switch Study[J].Journal of Clinical and Translational Hepatology,2018,6(1):25-34. 被引量:90
  • 2Rehermaun B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 2005, 5: 215-229.
  • 3Tan AT, Koh S, Goh V, et al. Understanding The imnamopathogenesis of chronic hepatitis B virus: an Asian prospective. J Gastroenterol Hepatol, 2008, 23: 833-843.
  • 4Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology, 2002, 122: 614-624.
  • 5Fisicaro P, Valdatta C, Boni C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut, 2009, 58: 974-982.
  • 6Ralainirina N, Poli A, Michel T, et al. Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol, 2007, 81: 144- 153.
  • 7Franzese O, Kennedy PT, Gehring AJ, et al. Modulation of the CD8+T-cell response by CD4+CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol, 2005, 79: 3322-3328.
  • 8Lau GK, Cooksley H, Ribeiro RM, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther, 2007, 12: 705-718.
  • 9Tjwa ET, van Oord GW, Hegmans JP, et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol, 2011, 54: 209-218.
  • 10Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti- viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol, 2003, 39: 595-605.

共引文献707

同被引文献26

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部